PURPOSE: Determining when to begin therapy with a long-acting bronchodilator and
inhaled corticosteroid in patients with COPD is challenging since no clinical trials have been …

Introduction This study aimed to characterize patients with chronic obstructive pulmonary
disease (COPD) newly prescribed a long-acting bronchodilator (LABD), and to assess …

Background No observational studies have evaluated the “real-world” effectiveness of dual
bronchodilation comprising a long-acting β2-agonist plus a long-acting muscarinic …

Background: The objective of the FLIGHT3 study was to evaluate the long-term safety and
efficacy of indacaterol/glycopyrrolate*(IND/GLY) versus an active comparator, IND, in …

In recent years, emphasis has shifted from preventing and treating chronic obstructive
pulmonary disease (COPD) to early prevention, early treatment, and disease stabilization …

Inhaled bronchodilator medications are central to the management of COPD and are
frequently given on a regular basis to prevent or reduce symptoms. While short-acting …

Abstract The Global Initiative for Chronic Obstructive Lung Disease (GOLD)
recommendations for the initial bronchodilator to use in newly diagnosed chronic obstructive …

Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder
characterized by usually progressive development of airflow obstruction that is not fully …

Background In patients with chronic obstructive pulmonary disease (COPD), the relationship
between short-term bronchodilator reversibility and longer-term response to bronchodilators …

Chronic obstructive pulmonary disease (COPD) is a common disease with an estimated
global prevalence of 11.7%, affecting almost 400 million people around the world. 1 In the …